What is the best approach to manage aggression and agitation in a patient with Lennox‑Gastaut syndrome?

Management of Aggression and Agitation in Lennox-Gastaut Syndrome

The management of aggression and agitation in patients with Lennox-Gastaut syndrome (LGS) requires careful consideration of antiseizure medications (ASMs) that can improve behavioral outcomes while avoiding agents that may worsen agitation, with benzodiazepines being particularly problematic despite their common use.

Primary Pharmacological Approach

First-Line ASM Selection for Behavioral Management

When managing a patient with LGS who exhibits aggression and agitation, prioritize ASMs that have demonstrated favorable cognitive and behavioral profiles rather than those that may exacerbate behavioral symptoms 1, 2.

Valproate remains the recommended first-line treatment for newly diagnosed or poorly controlled LGS 2. If behavioral symptoms persist or worsen:

• Add lamotrigine as first adjunctive therapy, using weight-adjusted dosing (50-100 mg for patients <25 kg on valproate, up to 300-400 mg for patients >25 kg not on valproate) 3
• Consider rufinamide as second adjunctive option if lamotrigine is insufficient 2

Critical Medication Considerations

Avoid or minimize benzodiazepines despite their widespread use in LGS, as they correlate with lower adaptive behavior scores and worse functional outcomes in adults with LGS 4. This is particularly important given that benzodiazepines (especially midazolam) pose excessive risk in managing severe agitation, with a 5-fold increased risk of adverse events compared to alternatives 5.

Consider cannabidiol (CBD) as adjunctive therapy when behavioral symptoms are prominent, as it has been associated with higher adaptive behavior scores in adults with LGS 4. This represents one of the few ASMs with positive behavioral correlations in this population.

Medications to Avoid

Do not use gabapentin - it has been reported to worsen myoclonic seizures and behavioral symptoms in LGS patients 3.

Exercise extreme caution with carbamazepine - it can cause seizure worsening in LGS, which may secondarily worsen behavioral symptoms 3.

Acute Agitation Management

If acute severe agitation requires immediate pharmacological intervention in the emergency setting:

• Avoid benzodiazepines, particularly midazolam, which significantly increases adverse events (OR 5.25) 5
• Consider quetiapine if antipsychotic use is necessary, as it demonstrated the lowest frequency of adverse events (OR 0.27 compared to haloperidol) in older adults with severe agitation 5
• Recognize that any sedating medication carries risk of respiratory depression, delirium exacerbation, and falls

Comprehensive Management Algorithm

Step 1: Optimize Seizure Control

Poor seizure control directly correlates with worse adaptive behavior and increased agitation 4. Target drop attacks specifically, as these dangerous seizures contribute to injury risk and behavioral deterioration.

Step 2: Review Current ASM Regimen

• If patient is on benzodiazepines: Consider gradual taper and replacement with cannabidiol or other evidence-based alternatives
• If using >2 ASMs: Simplify regimen when possible, as polypharmacy increases cognitive burden 2
• If behavioral symptoms emerged after ASM addition: Consider that medication may be causative

Step 3: Address Non-Seizure Factors

Agitation in LGS often stems from:

• Sleep disturbances - common in LGS and exacerbate behavioral symptoms 6, 7
• Communication difficulties - receptive communication is relatively preserved compared to expressive skills 4
• Physical discomfort or pain - may be difficult for cognitively impaired patients to communicate
• Environmental overstimulation - nonpharmacologic approaches should always be attempted first

Step 4: Long-term Behavioral Management

• Earlier age at LGS diagnosis predicts worse adaptive outcomes 4, so patients with childhood-onset disease require more intensive behavioral support
• High seizure frequency, EEG background slowing, and multifocal epileptiform abnormalities correlate with lower adaptive function 4
• Focus on improving daily living skills and socialization, which are particularly impaired domains 4

Critical Pitfalls to Avoid

Do not reflexively prescribe benzodiazepines for behavioral symptoms in LGS - while clonazepam is FDA-approved for LGS seizures, chronic benzodiazepine use correlates with worse behavioral outcomes 4 and poses significant safety risks 5.

Do not assume all agitation is psychiatric - worsening seizures, medication side effects, or delirium may present as behavioral changes. High EEG background slowing correlates with worse adaptive behavior 4.

Do not overlook medication-induced behavioral worsening - several ASMs can paradoxically worsen behavior in LGS patients, particularly gabapentin and potentially lamotrigine (rare reports of myoclonic jerk worsening) 3.

Quality of Life Focus

Always prioritize overall quality of life over seizure frequency alone 7. Management must balance seizure control against medication side effects, with particular attention to:

• Cognitive function preservation
• Behavioral stability
• Physical safety and fall prevention
• Social participation and adaptive skills

The goal is not complete seizure freedom (rarely achievable in LGS) but rather optimizing function and minimizing both seizure-related injuries and medication-related behavioral deterioration.